---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-161089"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:22:38.583885+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# CABA-201 shows no CRS/ICANS/SAEs in first two patients; B cell depletion and disease score improvements observed

## Summary
- First patient in IMNM cohort had creatinine kinase drop from 617 to 308 and TIS of 30 at week 12.
- First SLE patient had SLEDAI-2K score drop from 26 to 10 at week 4.
- Complete B cell depletion by day 15 post-infusion; immature naïve B cell repopulation seen at week 8 in IMNM patient.
- All chronic maintenance therapies discontinued for both patients except planned prednisone taper for SLE patient.
- 18 sites open, 5 patients enrolled as of June 12, 2024; initial data support current dose of 1e6 cells/kg.

## SEC filing metadata
- accession: 0001193125-24-161089
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312524161089/0001193125-24-161089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312524161089/d851455d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-161089
- JSON: https://secwatch.observer/filing/0001193125-24-161089.json
- Plain text: https://secwatch.observer/filing/0001193125-24-161089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.